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MATERIALS AND METHODS 
Monoclonal antibodies and flow cytometry.   
The monoclonal antibodies used in this project are all from eBioscience except as indicated: 
antibody to CD4 (anti-CD4; L3T4; PE, PE-Cy5.5), anti-CD8 (53-6.7; PE, PE-Cy5.5), anti-
CD11b (M1/70; biotin, PE-Cy5.5), anti-CD11c (N418; PE), anti-CD19 (6D5; PE), anti-CD25 
(PC61.5; APC, APC-Alexa 750, APC-Alexa 780), anti-CD27 (LG7F9; APC), anti-CD44 (1M7; 
FITC, Pacific Blue, eFluor 450), anti-B220 (RA3-6B2; biotin, FITC, APC), anti-CD45 (30-F11; 
PE-Cy5.5, PerCP-Cy5.5), anti-CD45.1 (A20; PerCP-Cy5.5, APC), anti-CD45.2 (104; PerCP-
Cy5.5, APC), anti-Thy1.2 (53-2.1; FITC, APC), anti-CD122 (5H4; PE), anti-c-Kit (2B8; FITC, 
PE, APC), anti-Gr1 (RB6-8C5; biotin, PE), anti-Sca-1 (D7, APC), anti-TCR (H57-597; PE, 
APC), anti-TCR (eBioGL3; PE, APC), anti-NK1.1 (PK136; FITC, PE, APC), anti-DX5 (DX5; 
FITC, PE), anti-Ter119 (BioLegend; Ter119; biotin), anti-hNGFR (Miltenyi Biotech; PE).  For 
detection of biotinylated antibodies, streptavidin–PE-Cy5.5 was used.  Cells were stained after 
blockade of Fc receptors for 15 minutes at 4 °C.  Excess antibodies were washed out by 1 
CBSS.  Cells were sorted on a FACSAria and were analyzed on a FACSCalibur (Becton 
Dickinson Immunocytometry Systems).  Data were acquired and analyzed with CellQuest Pro or 
Diva software (Becton Dickinson Immunocytometry Systems) or FlowJo software (TreeStar). 
All fluorescence data are plotted on a four-decade logarithmic scale with forward scatter, side 
scatter and cell numbers on a linear scale. 
 
Animals.   
C57BL/6 (B6) mice were originally purchased from Jackson Laboratory, and bred ever since in 
Caltech Laboratory Animal Facility.  Bcl11b
L2/L2
 mice were previously described (1).  
ROSA26R-EYFP mice were from Dr. Frank Costantini (Columbia University).  For some 
experiments, Bcl11b
L2/L2
 ROSA26R
EYFP/EYFP
 mice (“Bcl11bL2/L2  ROSA26R-YFP”) were 
generated by crossing Bcl11b
L2/L2  
mice with ROSA26R-YFP mice and breeding to double 
homozygosity.  Embryos of ROSA26R-YFP, Bcl11b
L2/L2
, Bcl11b
L2/L2  ROSA26R-YFP, B6, 
and (B6DBA/2)F2 genotype at E13.5 were generated from timed-mating in our colony or were 
obtained from the Caltech Genetically Engineered Mouse facility.  All animal protocols were 
reviewed and approved by the Institute Animal Care and Use Committee of the California 
Institute of Technology.   
 
Hematopoietic progenitor cells from fetal liver and adult bone marrow. 
Fetal liver cell samples (E13.5, date of plug = E0.5) were depleted of cells positive for Ter119, 
CD19 and Gr1 by biotinylated antibodies and streptavidin microbeads (Miltenyi Biotec) 
followed by magnetic-stand separation.  Samples were further enriched by c-Kit-PE staining and 
anti-PE microbeads (Miltenyi Biotec) followed by positive magnetic selection.  Bone marrow 
cells were depleted of cells positive for Ter119, CD5, CD19, B220, Gr1 and Mac1 (Mouse 
hematopoietic progenitor enrichment kit, StemCell Technologies), followed by c-Kit-PE staining 
and anti-PE microbeads.  The antibody cocktail for sorting of fetal liver HPCs contained anti-
hNGFR-PE, anti-c-Kit-FITC, anti-CD27-APC, streptavidin–PE-Cy5.5 (to remove residual Lin+ 
cells) and 7AAD; 7AAD
-
 streptavidin
-
 hNGFR
+
 c-Kit
+
 CD27
+
 cells were sorted as fetal liver 
HPCs.  Bone marrow HPCs were sorted as 7AAD
-
 streptavidin
-
 (YFP
+
, when appropriate) c-Kit
+
 
and Sca-1
+
 (using anti-Sca-1-APC). 
 
Retroviral Cre infection and sorting of hematopoietic progenitor cells. 
The Cre retroviral vector was constructed and kindly provided by Dr. Tom Taghon (University 
of Ghent).  In this vector, Cre was inserted into a bicistronic LZRS retroviral backbone 
containing a IRES–hNGFR cassette.  Particles were packaged with the Phoenix-Eco packaging 
cell line following standard protocols. Viral supernatants were collected and were stored in 
aliquots at -80 °C until use. For transduction, non–tissue culture plates (Corning) were coated 
overnight at 4 °C with RetroNectin (25 g/ml, Takara), then were blocked for 30 min with 2% 
(wt/vol) BSA in PBS and finally incubated for 4 h at 37 °C with retroviral supernatant.  After 
coating, viral supernatant was removed and fetal liver hematopoietic progenitor cells (HPCs) 
were added immediately in OP9 coculture medium as described below, with 5 ng/ml each of 
Flt3L, IL-7 and SCF.  Cells were then cultured on the virus-coated plates for 44 hours for 
transduction, and successfully transduced cells were sorted afterwards for hNGFR expression 
together with lymphoid progenitor-enriched phenotype.   
 
Bone marrow HPCs were first cultured on tissue culture treated plates (Corning) for 24 hours in 
OP9 coculture media with 20 ng/ml of IL-3, 50 ng/ml of IL-6, 50 ng/ml of SCF, 5 ng/ml of Flt3L 
and 5 ng/ml of IL7.  Then, cells were transferred onto virus coated plates and cultured for 
transduction for 44 hours with the same cytokines and concentrations.   
 
Cell culture conditions.   
Sorted HPC were transferred to ~80% confluent cultures of OP9-DL1 cells.  Conditions for OP9-
DL1 and OP9-control stromal cocultures have been described (2, 3). OP9 coculture media 
contains 20% FBS (Hyclone), 50 nM -mercaptoethanol, -MEM and Pen-Step-Glutamine 
(Gibco).  All cytokines were from Peprotech except where indicated otherwise.  Fetal liver HPCs 
were co-cultured with 5 ng/ml each of Flt3L and IL-7 for about 9 days, except as indicated (Fig. 
S2).  Then, DN1, DN2a and DN2b/3 cells were sorted based on the expression of c-Kit and 
CD25 within the CD45
+
 population.  Half of the cells in each sorted samples were transferred to 
TRIZOL Reagent (Invitrogen) for RNA extraction, and the remaining cells were cocultured 
again with 5 ng/ml each of Flt3L and IL-7 for another 7 to 9 days.  The cells were then re-sorted 
as “DN1”, DN2a, and DN2b for RNA analysis.  Bone marrow LSK cells were co-cultured with 
OP9-DL1 with 5 ng/ml each of Flt3L and IL-7 for about 12 days.  Then, cells were transferred 
onto fresh OP9-DL1 monolayer with 5 ng/ml of Flt3L and 1 ng/ml of IL-7 for 8 days more 
before sorting.  The cell sorting and following procedures were the same as of fetal liver 
experiments.   
 
Two variations were incorporated in some experiments.  In some experiments YFP expression 
from the ROSA26R locus was used as a genetic marker for successful Cre activity.  YFP
+
 CD45
+
 
cells were gated initially for sorting into DN subsets.  In certain other experiments, e.g. in Fig. 
S9, cells beginning to express NK1.1 were excluded from the DN2 and DN1 sorted populations 
and collected separately for analysis, to distinguish behavior and gene expression of potentially 
committed NK precursors from those of early T-lineage cells. 
 
Because Bcl11b deletion causes cells to maintain high levels of RNA encoding four growth 
factor receptors, Kit, Flt3, Il7r, and Il2rb, the control of cytokine signals was of interest. Two 
factors known to be essential for early T cell development are IL-7 and Kit ligand (4).  
Concentrations of IL-7 between 1 ng/ml and 5 ng/ml affected the progression of control cells 
from DN2 to DN3, but had little effect on Bcl11b-deleted cells, except a minor effect on CD44 
staining alone (Fig. S2 & data not shown).  The addition or omission of 1 ng/ml Kit ligand in the 
primary cultures had no effect on the phenotype (data not shown). 
 
Demonstration of the myeloid potential of Bcl11b-deficient DN2a cells depended on the 
presence of myeloid-promoting cytokines, on the removal of cells from Notch signals, and on 
limiting the overgrowth of NK-like cells.  For the experiment shown in Fig. 2C, bone marrow 
LSK from ROSA26R-YFP and Bcl11b
L2/L2
-ROSA26R-YFP mice were first cultured for 20 days 
on OP9-DL1 to generate T-cell precursors.  DN1, DN2a, DN2b/3 (wild-type control) and DN-
intermediate (DNINT, Bcl11b
L2/L2
) were then sorted (Fig. S3) and cocultured with OP9-control 
cells and 5 ng/ml of M-CSF, omitting Flt3L and IL-7 (Fig. 2C).  YFP
+
 CD45
+
 cells were stained 
for myeloid cell markers Mac1 and Gr1 after 9 days of coculture. 
 
RNA extraction and quantitative real-time RT-PCR.   
RNA was isolated from sorted cells in 750 l TRIZOL Reagent following the manufacture’s 
protocol.  RNA was reverse-transcribed into cDNA with Superscript RT III (Invitrogen).  SYBR 
Greener qPCR SuperMix (Invitrogen) and a 7900 HT Fast Real-time PCR System (Applied 
Biosystems) were used for real-time PCR with primers synthesized by Eurofins, as published (5-
8), plus additional primers listed in Supplementary Table 2. Relative expression was calculated 
for each gene by the CT (change in cycling threshold) method with GAPDH or -actin for 
normalization.  
 
Multiple experiments using fetal liver precursors and three using bone marrow precursors were 
processed for gene expression analysis by realtime quantitative RT-PCR.  DN1-like cells and 
DN2a cells were analyzed from secondary cultures of Bcl11b-deleted samples in all experiments, 
compared with various controls from primary and/or secondary cultures.  However, the 
distribution of differentiated subsets of Cre+ controls varied from experiment to experiment, so 
that the comparisons made were not the same in all experiments, and the efficiency of Bcl11b 
deletion in some cases was not adequate for sensitive analysis of its effects (e.g. Fig. S4).  Also, 
overlapping but not identical sets of genes were assayed in samples from different experiments.  
Therefore, rather than show only replicates of the data for control and Bcl11b-deleted samples 
and genes common to all experiments, Fig. 3 (and Fig. S7) and Figs. S8 and S9 show extended 
sets of data from three experiments that combined the broadest ranges of genes tested, and the 
broadest sets of samples.  Fig. 3 (and Fig. S7) and Fig. S8 also had the most efficient deletion of 
Bcl11b in the starting populations.  The data shown in Fig. S9 were from samples in which 
deletion was only about 90% efficient but where the stringent sorting criteria provided additional 
value, i.e. separation of NK1.1
+
 subsets and direct comparison between Bcl11b-deficient cells 
and those minority wildtype cells that maintained a similar developmentally retarded phenotype.  
The major gene expression effects described in the text were each corroborated in at least one 
additional independent experiment.  MATLAB 7.8.0 (2009a) was used to generate heatmaps 
from log10 transformed quantitative PCR data, with values for each gene in normal (B6) primary 
culture DN2a cells set as 1.  The script is available upon request. 
SUPPLEMENTARY TEXT 
 
GENERAL STRATEGY AND FEATURES OF SYSTEM: COMPARISON OF IN VITRO 
AND IN VIVO DEVELOPMENT. 
To track precursors with and without Bcl11b under T-cell development conditions, the OP9-DL1 
coculture system (9, 10) was used to provide Notch/Delta signals in the presence of the cytokines 
IL-7 and Flt3L.  It is thought that these stromal cells naturally supply Kit ligand as well as other 
possible growth and survival signals to the developing precursors in addition to the Notch ligand.  
T cells normally develop all the way from stem cells through all major early thymic checkpoints 
in this system, to acquire  or  T-cell receptors.  Growth in this system can be extensive.  A 
convenient aspect of this system is the ability to “stop time”: T-cell differentiation is only 
initiated when the cells are plated on the OP9-DL1 stroma, so that genes important for T-cell 
development can be deleted in the precursors in vitro before culture with OP9-DL1, and the 
affected cells can be purified efficiently to seed these cultures before any lineage-specific 
selective effects can occur.   
 
The stage at which most Bcl11b germline knockout cells have been reported to arrest in vivo is 
the DN3 stage, after the “DN2b” stage (11-13).  Passage beyond this stage in vivo and in vitro 
depends on successful rearrangement of either the TCR chain gene or successful rearrangement 
of both the TCR and TCR genes (4), and TCR-chain expression per se is needed for the cells 
to undergo the massive proliferation and differentiation event of -selection that leads them to a 
CD4
+
 CD8
+
 “double positive” (DP) stage.  However, the defect of Bcl11b germline knockout 
cells prevents efficient differentiation through -selection even if pre-rearranged TCR 
transgenes are present (11).  Some CD8
+
 cells are generated, but these appear to be mostly or 
entirely TCR cells (14).  The loss of Bcl11b is associated with loss of viability not only at the 
-selection checkpoint in vivo but also later, if it is deleted at the DP stage (15).  In fact, it is an 
interesting problem why loss of a reputed tumor suppressor (16, 17) could be so deleterious to 
cell survival.  These concerns about viability effects and the need to generate robustly 
differentiating control cells for comparison guided our choice of experimental conditions. 
 
One known abnormality of the OP9-DL1 stromal system, as compared to normal T-cell 
development, is an increased expansion of cells in the DN2a/2b stages, presumably reflecting 
supranormal levels of stage-specific growth stimuli.  This tendency is exacerbated with precursor 
cells derived from adult bone marrow as compared to precursors derived from fetal liver (18, 
19), and that is why we have preferred fetal liver precursors for most experiments here.  Another 
uncertainty is whether lineage commitment is executed as crisply at the DN2a/2b transition (20, 
21) in cells developing in prolonged culture in vitro as it is in vivo.  However, in extensive 
experiments to compare gene expression patterns of fetal liver-derived DN pro-T cells 
developing in vitro with those of cells developing in vivo in the fetal or adult thymus, we have 
found that the great majority of 30-60 genes tested are regulated indistinguishably (D. D. 
Scripture-Adams, K. J. Elihu, C. Georgescu and E. V. R., in preparation)(for discussion of the 
significance of these genes, see (5, 20, 22-25)).  Importantly, the cells developing in vitro do shut 
down expression of stem/progenitor genes at the DN3 stage comparably to normal adult 
thymocytes. Thus the system overall appears to provide signals faithful enough to guide a 
broadly accurate program of T-cell development.  
 
 Fig. S1.  Deletion of the Bcl11b locus and generation of the ROSA26R-YFP recombinase 
activity marker using retroviral Cre recombinase transduction.  (A) Details of construction of the 
floxed Bcl11b
L2
 allele are from ref. (1).  LoxP sequences were placed 105 bp upstream of Exon4 
and 291 bp downstream of the stop codon, respectively. Upon retroviral-Cre transduction, Exon4 
of Bcl11b is deleted.  In gene expression analysis, Bcl11b exon 2-4 primers (red arrows) are used 
to detect the predominant transcript from the wildtype Bcl11b locus, which includes an 
Exon2/Exon4 splice.  (B) Cre-modifications of Bcl11b
L2
 and ROSA26R-YFP alleles. Expression 
of YFP marks activity of retroviral-Cre. 
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Fig. S2.  Proliferation of Bcl11b-deleted cells.  (A) Emergence of DN2a cells from control and 
Bcl11b-deleted DN2a and DN2b/3 cells in OP9-DL1 secondary culture.  Y axis shows 
proliferative yield relative to input cell number at the start of the secondary culture.  (B) 
Emergence of DN1-like cells from wildtype and Bcl11b-deleted DN2a and DN2b/3 cells in OP9-
DL1 secondary culture.  Note that Bcl11b-deleted DN2a cells give rise to more DN1-like and 
DN2a cells than any other populations.  (C) and (D) Another set of independent experiments, as 
for (A) and (B).  (E) Effect of concentration of IL7 on the transition of DN2a to DN2b/3 in OP9-
DL1 primary culture.  Note that less IL7 pushes control (Bcl11b+/+ Cre+) cells to pass the DN2a 
to DN2b/3 transition, whereas Bcl11b-deficient (Bcl11b
L2/L2
 Cre+) cells remain stalled.  (F) 
Results in (E) plotted as bar graph.   
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 Fig. S3.  Developmental arrest of Bcl11b-deficient bone marrow derived cells.  (A) Experimental 
scheme. BM LSK from ROSA26R-EYFP and Bcl11b
L2/L2
 ROSA26R-EYFP mice were isolated 
and transduced with hNGFR-Cre retrovirus, and BM LSK that had become YFP+ due to Cre 
activity were sorted and co-cultured with OP9-DL1. (B) After 20 days of culture, the indicated 
DN subsets of cells were sorted (red populations).  A fraction of each population was returned to 
OP9-DL1 co-culture with reduced IL-7 for 9 days (C) or 12 days (D). DN2a and DN2b/3 cells of 
ROSA26R-EYFP (Bcl11b+/+, YFP) developed to the CD4/CD8 double positive stage, while 
DNINT and DN2a cells of Bcl11b
L2/L2
 x ROSA26R-EYFP (Bcl11bL2/L2, YFP) stalled at DN 
stages.  
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 Fig. S4.  Enhanced self-renewal capacity of Bcl11b-deleted cells at the DN2a and DN1-like 
stages.  (A) Phenotypes of primary cultures on OP9-DL1.  The DN2b/3 population developed in 
this Bcl11b
L2/L2
 Cre+ sample consisted primarily of cells that did not delete Bcl11b completely 
(as shown by gene expression analysis in C).  (B) Progeny of sorted DN2a and DN2b cells from 
control and Bcl11b
L2/L2
 Cre+ samples shown in A, after secondary culture.  On transfer to 
secondary OP9-DL1 coculture longer term, DN2b as well as DN2a cells from Bcl11b-deleted 
samples gave rise to DN1-like and DN2a cells. (C) Bcl11b gene expression analysis: heat map 
format normalized to levels of expression in control DN2a cells.  Results for Bcl11b exon 2-4 
show that although initial Bcl11b deletion was incomplete, the secondary populations with both 
DN1-like and DN2a phenotype have extensive deletion of Bcl11b, indicating preferential 
expansion of Bcl11b-deleted cells.  Similar results were obtained in at least three independent 
experiments.   
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Fig. S5.  Generation of NK1.1
+
 cells from fetal liver hematopoietic progenitor cells in OP9-DL1 
primary culture: enhanced emergence of NK1.1
+
 DN1-like cells when Notch signaling is limited.  
Histograms show NK1.1 staining of the indicated gated subsets of Cre-treated wildtype (blue 
lines, open curves) and Bcl11b
L2/L2
 cells (red, closed curves) in primary OP9-DL1 culture.  
Results show generation of NK1.1
+
 cells in the DN1-like population of the Bcl11b-deleted cells.  
Also shown is increased NK1.1
+
 cell emergence in response to inhibition of Notch signaling by 1 
M GSI, added to OP9-DL1 cultures of the indicated populations for the last four days before 
harvest.  
 
 
  
Fig. S6.  Growth advantage of DN1-like and DN2a Bcl11b-deleted cells after transfer to OP9-
control co-culture.  (A) Preferential growth of Bcl11b-deleted DN2a cells generated from 
secondary OP9-DL1 coculture, when transferred to OP9-control co-culture.  (B) Long term 
growth of both wildtype and Bcl11b-deleted DN1-like cells generated from secondary OP9-DL1 
coculture in OP9-control co-culture.  Note that in the presence of IL-7 and Flt3L, additional 
cytokines have no effect on the growth of Bcl11b-deleted cells.  
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 Fig. S7.  Sorting gates and measured values of RNA expression for control and Bcl11b-deleted 
samples from the experiment shown in Fig. 3.  (A) Phenotypes and sorting gates for fetal liver 
HPC-derived samples from primary culture.  Gate positions are indicated on the control samples.  
The same gates were applied to Bcl11b-deleted cells.  (B) Phenotypes and sorting gates for 
samples from secondary cultures.  Note that the Bcl11b-deficient DN2b/3 primary gate enriched 
for cells that were able to progress beyond the DN2 stage in secondary culture.  These cells were 
found not to have deleted Bcl11b (data for this complex population not shown), whereas the cells 
generated from this population that remained DN2a-like or DN1-like were fully deleted as 
shown in (C) and Fig. 3.  (C) Bar graph of actual gene expression levels for pro-T cell genes, 
stem-cell genes, and alternative-lineage genes of interest from broader analysis shown in Fig. 3. 
Samples derived from control cells are shown in shades of blue, samples from Bcl11b-deleted 
cells are shown in shades of brown, black (long-term DN2a cells) or red (long-term NK-like 
cells).  Data are shown on a log10 scale relative to -actin.  The lower boundary of this graph (<3 
 10-5 actin units) is considered too low to quantitate.   
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Fig. S7
 Fig. S8. Gene expression analysis of the effect of Bcl11b deletion in early T cells derived from 
fetal liver progenitors.  Data from a different, independent experiment from that in Fig. 3 and 
Fig. S7 are shown.  (A) Phenotypes and gating from primary cultures on OP9-DL1.  (B) 
Phenotypes and gating from secondary cultures on OP9-DL1.  (C)  Heat map of gene expression 
effects.  Similar results were obtained in two other experiments, one from fetal liver precursors 
and one from bone marrow precursors. 
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Fig S8
 Fig. S9. Gene expression analysis of the effect of Bcl11b deletion in early T cells derived from 
fetal liver progenitors.  Direct comparison between Bcl11b deleted subsets and those cells from 
control culture that exhibit matching phenotypes.  Data from a third, independent experiment 
from those in Fig. 3 (Fig. S7) and Fig. S8 are shown.  Bcl11b-deficient samples shown were 
from secondary cultures seeded with sorted DN2a cells from primary culture.  Sorting gates for 
RNA analysis samples in this experiment were set to exclude NK1.1
+
 cells from the DN 
populations, to be collected separately.  This experiment highlights the overall similarity between 
longterm cultured Bcl11b-deficient cells maintaining an NK1.1-negative, TCR-negative DN2a 
phenotype (maroon bars) and those cultured normal cells that still have similar T-cell precursor 
phenotypes in primary and secondary culture (left hand groups of blue bars).  It also shows the 
similarity between gene expression in longterm Bcl11b-deficient cells that are still NK1.1-
negative but adopting DN1-like phenotype (light orange) and gene expression in fully NK1.1
+
 
cells from both normal (cyan) and Bcl11b-deficient (red) phenotypes (right hand bars). Gene 
expression values determined by quantitative real-time RT-PCR are shown on a scale with -
actin set as 1.  Asterisk notes an anomalously high value that was not reproducible. 
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Fig. S10. Proposed role of Bcl11b in T-cell lineage specification and commitment.  Separate 
layers of regulatory influence are shown in terms of distinct transcription factor cohorts 
(horizontal bars) acting during T-cell specification, with recurrent inputs from Notch/DL1 
signaling. Arrows: proposed transcriptional induction. Lines with bars: proposed transcriptional 
repression. 
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Fig. S10
 Fig. S11.  Fewer TCR cells develop from Bcl11b-deleted cells than controls.  (A) Fewer 
TCR cells developed from Bcl11b-deleted fetal liver HPCs in primary OP9-DL1 coculture.  
(B) Fewer TCR cells developed from Bcl11b-deleted DN2a and DN2b cells than from equal 
numbers of controls in secondary OP9-DL1 coculture.  (C) Phenotypic analysis of TCR cells 
in (A): downregulation of c-Kit with acquisition of TCR receptor.  
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SUPPLEMENTARY TABLES 
 
Table S1.  Table of cell recoveries from control and Bcl11b-deleted precursors in primary and 
secondary OP9DL1 cocultures 
 
Table S2.  Primers used in realtime quantitative PCR.  Primers not listed have been published 
previously as described in Methods (5-8). 
 
B3 Experiment 1 10 7.06 (17.6) 45.9 (58) 32.3 (18.8)
B6 Experiment 2 10 3.73 (13.1) 44.8 (58.4) 37.1 (19.2) 9 0.67 (8.27) 0.022 (0.47) 31.4 (20.2)
B9 Experiment 3 8 13.7 (11.2) 61.8 (69.7) 14.6 (16.4) 11 4.4 (21.4) 1.31 (5.59) 24 (9.56)
C1 Experiment 4 9 8.03 (3.46) 44.3 (73.9) 33.5 (16.3) 12 25.3 (35.6) 2.24 (59.9) 29.6 (1.95) 3.89 (23.3) 0.44 (33.3) 43.7 (10.8)
C3 Experiment 5 9 1.39 (9.2) 27.1 (41.6) 42.2 (30.8) 7 0.68 (29.5) 15.6 (64.5) 71 (3.76) 0.043 (21.4) 0.42 (45) 32.5 (11.7)
C12 Experiment 6 12 1.89 (16.4) 16.2 (46.1) 58.8 (23) 9 76.1 (86.1) 12.1 (8.67) 6.19 (1.69) 18.8 (20.1) 17.8 (11.3) 32 (20.6)
C14 Experiment 7 10 8.49 (16.8) 42.7 (48.6) 21.9 (21.2) 9 41.3 (36.4) 25.7 (51.5) 20.3 (5.47) 27.2 (32.4) 9.76 (44.1) 15.9 (12.1)
C10 Experiment 8 21 3.06 (69.9) 6.91 (7.54) 74 (10.4) 9 (3.83) (70.6) (22.5) 2.54 (4.38) 11.5 (71.3) 76.2 (21.8)
Note: 1. Black samples are wildtype controls + Cre;  red samples in parentheses are Bcl11b-floxed cells +Cre.
2. C10 used bone marrow precursors.
3. Numbers indicate percentage of the population in c-kit/CD25 plot, except C10, where numbers are from a CD44/CD25 plot.
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TABLE S1. 
Cell recoveries from control and Bcl11b-deleted precursors in primary and secondary OP9DL1 cocultures 
Table S2  Primers for quantitative PCR analysis  
  Forward Primer Reverse Primer 
Bcl11b E4 GGACAGCAATCCTTTCAACC ATGACTCGGTCGAAGGCACT 
Bcl11b 2-4 AGGTCACCCCTGATGAAGAT CATGTGTGTTCTGTGCGTGCT 
Bmi TGGCTCGCATTCATTTTATG TACCCTCCACACAGGACACA 
Ifng CTTCTTCAGCAACAGCAAGG TGAGCTCATTGAATGCTTGG 
IL17 TCCAGAAGGCCCTCAGACTA TGAGCTTCCCAGATCACAGA 
c-myc CAGCCCTGAGCCCCTAGT GATGGAGATGAGCCCGACT 
CCR9 GATTGGCGTCCGATCCAC CATGTAGTCATCTGTGGAAGCAG 
CD19 E4/5 TGTCTCCGAGGAAACCTGAC CTGGGACTATCCATCCACCA 
CDK2 AAATTCATGGATGCCTCTGC ACGGTGAGAATGGCAGAAAG 
CDK4 CTCTGGTACCGAGCTCCTGA CAAAGATTTTCCCCAACTGGT 
CDK6 GAGGCACCTGGAGACCTTC GGGCTCTGGAACTTTATCCA 
Ccnd1 CTCTCCTGCTACCGCACAAC TGACTCCAGAAGGGCTTCAA 
Ccnd2 TCCCGCAGTGTTCCTATTTC CCAAGAAACGGTCCAGGTAA 
Ccnd3 CGCCCCTGACTATTGAGAAG CCAGGTCCCACTTGAGCTT 
CyclinA CTGTCTCTTTACCCGGAGCA AACGTTCACTGGCTTGTCTTC 
Eomes ACCCAGCTAAAGATCGACCA GAAGTTTTGAACGCCGTACC 
Flt3 GAAGCCGCCAACTACACAGT CGTCCTGGTTTTCCATCTTC 
HoxB4 AAAGAGCCCGTCGTCTACC GCGTCAGGTAGCGATTGTAG 
Lbd1 ACACCAACAACAGCAACAGC CGTCAAACTGGGTGTTCTCC 
Lmo1 TCTACACCAAGGCCAACCTC CATCTCAAAAGCTGGGATCA 
Lmo2 CTCAGCTGTGACCTCTGTGG CTTTGTCTTTCACCCGCATC 
Lyl1 CAGGACCCTTCAGCATCTTC ACGGCTGTTGGTGAACACTC 
Mef2c AAGAAACACGGGGACTATGG TCAGTGCAATCTCACAGTCG 
Nfil3 GTTACAGCCGCCCTTTCTTT AATGGGTCCTTCTGTTGTCC 
Notch2 CAGTGTCGAGGTGGTCAAGA ACCATTCTGACAGCGGTTTT 
p16 CTTTGTGTACCGCTGGGAAC CTGAGGCCGGATTTAGCTCT 
p18 CGTCAACGCTCAAAATGGAT TCAAATTGGGATTAGCACCTC 
p19 ATCCCGGAGACCCAGGAC CGAATCTGCACCGTAGTTGA 
p53 CCTGGCTGTAGGTAGCGACT AATGTCTCCTGGCTCAGAGG 
PCNA CAAGTGGAGAGCTTGGCAAT TCAGGTACCTCAGAGCAAACG 
PLZF AACGAGGCAGTGGAGCAG TGCATTCTCAGTCGCAAACT 
Rorgt TGTCCTGGGCTACCCTACTG GGATCCCAGATGACTTGTCC 
TCRgV2 CGAAGCTATCTACTACTGTTCC  
TCRgV3 ATCGGATGAAGCCACGTACT  
TCRgV4 TCCTTGGAGGAAGAAGACGA  
TCRgV5 TCCTTGGAGGAAGAAGACGA  
TCRgC1  GAAGGAAAATAGTGGGCTTGG 
Zbtb32 GCGGTACTAGGAGGCAGCTA TGGGCTGATTAGTCTTGTGG 
Zeb1 CCAGGTGTAAGCGCAGAAAG TTGTCTTCATCATCGGAATCTG 
Zeb2 ATCAATGAAGCAGCCGATCA TGCGTCCACTACGTTGTCAT 
Zfp105 CCTGGAGCTTCATGGGAAC GGGGCTTCTCCGAGTCAT 
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